S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:STSA

Satsuma Pharmaceuticals - STSA Earnings Date, Estimates & Call Transcripts

$5.88
-0.12 (-2.00%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.84
$5.99
50-Day Range
$2.90
$6.10
52-Week Range
$2.51
$6.52
Volume
38,135 shs
Average Volume
61,807 shs
Market Capitalization
$185.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Earnings Summary

Upcoming
Earnings Date
Nov. 8Estimated
Actual EPS
(May. 10)
-$0.49 Missed By -$0.01
Consensus EPS
(May. 10)
-$0.48
Last Year's Q2 EPS
(5/11/2021)
-$0.48
Skip Charts & View Estimated and Actual Earnings Data

STSA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

STSA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Satsuma Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.43)($0.43)($0.43)
Q2 20221($0.44)($0.44)($0.44)
Q3 20221($0.45)($0.45)($0.45)
Q4 20221($0.48)($0.48)($0.48)
FY 20224($1.80)($1.80)($1.80)

STSA Earnings Date and Information

Satsuma Pharmaceuticals last issued its quarterly earnings results on May 10th, 2022. The financial services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.01. Satsuma Pharmaceuticals has generated ($1.92) earnings per share over the last year (($1.92) diluted earnings per share). Earnings for Satsuma Pharmaceuticals are expected to grow in the coming year, from ($1.88) to ($0.98) per share. Satsuma Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 8th, 2022 based off prior year's report dates.

Satsuma Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/8/2022
(Estimated)
        
5/10/2022Q1 2022($0.48)($0.49)($0.01)($0.49)
3/15/2022Q4 2021($0.47)($0.49)($0.02)($0.49)
11/9/20219/30/2021($0.51)($0.42)+$0.09($0.42)
8/10/20216/30/2021($0.41)($0.38)+$0.03($0.38)
5/11/20213/31/2021($0.42)($0.48)($0.06)($0.48)
3/24/202112/31/2020($0.53)($0.72)($0.19)($0.72)
11/10/20209/30/2020($0.69)($0.69)($0.69)
8/12/2020Q2 2020($0.72)($0.65)+$0.07($0.65)
5/12/2020Q1 2020($0.67)($0.6758)($0.0058)($0.68)
3/10/202012/31/2019($0.81)($0.62)+$0.19($0.62)
11/12/2019Q3($1.01)($2.26)($1.25)($2.26)
1/30/2014Q4 2013$0.35$0.35$0.35$115.64 million$113.51 million
10/24/2013Q3 2013$0.40$0.33($0.07)$0.33$83.73 million$114.44 million
7/25/2013Q2 2013$0.36$0.44+$0.08$0.44$79.06 million$122.42 million  
4/24/2013Q1 2013$0.35$0.36+$0.01$0.36$78.50 million$114.46 million
1/24/2013Q4 2012$0.53$0.52($0.01)$0.71
10/25/2012Q3 2012$0.49$0.49$0.49
7/26/2012Q2 2012$0.37$0.51+$0.14($4.11)
4/25/2012Q1 2012$0.28$0.30+$0.02$0.39
1/25/2012Q4 2011$0.23$0.24+$0.01$0.24
10/25/2011Q3 2011$0.11$0.18+$0.07$0.18
7/27/2011Q2 2011$0.06$0.12+$0.06$0.12
4/19/2011Q1 2011($0.29)$0.09+$0.38$0.09
1/25/2011Q4 2010($0.68)($0.76)($0.08)$11.27
10/19/2010Q3 2010($3.95)$1.32+$5.27$1.32
7/27/2010Q2 2010($66.45)($73.68)($7.23)($73.68)
4/27/2010Q1 2010($131.58)($112.37)+$19.21($112.37)
2/1/2010Q4 2009($28.95)($421.84)($392.89)($421.84)
10/22/2009Q3 2009($42.76)($299.21)($256.45)($10.85)
7/23/2009Q2 2009($41.45)($42.96)($1.51)($42.96)
4/23/2009Q1 2009($42.76)($31.45)+$11.31($31.45)
1/27/2009Q4 2008($167.76)($167.57)+$0.19$115.32
10/21/2008Q3 2008$13.16$6.32($6.84)$6.32
7/22/2008Q2 2008$7.89$14.80+$6.91$14.80
4/21/2008Q1 2008$13.16$3.68($9.48)$3.68
1/28/2008Q4 2007$21.71$21.45($0.26)$21.45












Satsuma Pharmaceuticals Earnings - Frequently Asked Questions

When is Satsuma Pharmaceuticals's earnings date?

Satsuma Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 8th, 2022 based off last year's report dates. Learn more on STSA's earnings history.

Did Satsuma Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Satsuma Pharmaceuticals (NASDAQ:STSA) missed the analysts' consensus estimate of ($0.48) by $0.01 with a reported earnings per share (EPS) of ($0.49). Learn more on analysts' earnings estimate vs. STSA's actual earnings.

How much profit does Satsuma Pharmaceuticals generate each year?

Satsuma Pharmaceuticals (NASDAQ:STSA) has a recorded net income of -$51.17 million. STSA has generated -$1.92 earnings per share over the last four quarters.

What is Satsuma Pharmaceuticals's EPS forecast for next year?

Satsuma Pharmaceuticals's earnings are expected to grow from ($1.88) per share to ($0.98) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:STSA) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.